Francoise Bono, PhD, Named Chief Scientific Officer to Lead Preclinical Activities Olivier de Beaumont, MD, MBA, Appointed Chief Medical Officer to Lead Clinical Development and Operations, Medical and Regulatory Affairs Paris , March 1, 2017 – 6 pm CET – Onxeo S.A. , a biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, is pleased to announce the appointments of Francoise Bono, PhD, to the role of Chief Scientific Officer and Olivier de Beaumont, MD, MBA, to the role of Chief Medical Officer.